Thoratec HeartMate Receives Long-Awaited Destination Therapy Indication
This article was originally published in The Gray Sheet
Executive Summary
Thoratec will target major transplant and open-heart surgery centers in a new marketing initiative to promote the HeartMate SNAP-VE left ventricular assist device as a destination, "alternative-to-transplant" therapy for end-stage heart failure. FDA approved a PMA supplement for the indication on Nov. 6
You may also be interested in...
Thoratec's HeartMate II Implant Boosts Stroke-Free Survival Four-Fold - Study
Thoratec's next-generation HeartMate II continuous-flow left ventricular assist device enables a more than four-fold increase in two-year survival rate free from stroke and reoperation compared with the firm's HeartMate XVE pulsatile-flow LVAD, according to study data unveiled Nov. 17
Thoratec's HeartMate II Implant Boosts Stroke-Free Survival Four-Fold - Study
Thoratec's next-generation HeartMate II continuous-flow left ventricular assist device enables a more than four-fold increase in two-year survival rate free from stroke and reoperation compared with the firm's HeartMate XVE pulsatile-flow LVAD, according to study data unveiled Nov. 17
Patient-Reported Outcomes In Device Trials: FDA Guidance Under Review
FDA is reviewing a draft guidance on use of patient-reported outcome data in device evaluations, according to Division of Cardiovascular Devices Medical Officer Neal Muni, MD